Guo S, Jansen-Olesen I, Olesen J, Christensen SL. Role of PACAP in migraine: an alternative to CGRP? Neurobiol Dis. 2023;176:105946.

Article  CAS  PubMed  Google Scholar 

Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.

Article  CAS  PubMed  Google Scholar 

Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132(Pt 1):16–25.

Article  PubMed  Google Scholar 

Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. 2023;24(1):16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waliszewska-Prosół M, Vuralli D, Martelletti P. What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? J Headache Pain. 2023;24(1):163.

Article  PubMed  PubMed Central  Google Scholar 

Ernstsen C, Christensen SL, Rasmussen RH, et al. The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target? Brain. 2022;145(7):2450–60.

Article  PubMed  Google Scholar 

Frimpong-Manson K, Ortiz YT, McMahon LR, Wilkerson JL. Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics. Front Mol Neurosci. 2024;17:1355281.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283–357.

Article  CAS  PubMed  Google Scholar 

Ashina H, Christensen RH, Hay DL, et al. Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine. Nat Rev Neurol. 2024;20(11):660–70.

Article  PubMed  Google Scholar 

Hirabayashi T, Nakamachi T, Shioda S. Discovery of PACAP and its receptors in the brain. J Headache Pain. 2018;19(1):28.

Article  PubMed  PubMed Central  Google Scholar 

Jansen-Olesen I, Hougaard PS. PACAP and its receptors in cranial arteries and mast cells. J Headache Pain. 2018;19(1):16.

Article  PubMed  PubMed Central  Google Scholar 

Pedersen SH, la Cour SH, Calloe K, et al. PACAP-38 and PACAP(6–38) degranulate rat meningeal mast cells via the orphan MrgB3-receptor. Front Cell Neurosci. 2019;13:114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fahrenkrug J. PACAP–a multifacetted neuropeptide. Chronobiol Int. 2006;23(1–2):53–61.

Article  CAS  PubMed  Google Scholar 

Ashina M, Doležil D, Bonner JH, et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia. 2021;41(1):33–44.

Article  PubMed  Google Scholar 

Guo S, Rasmussen RH, Hay-Schmidt A, et al. VPAC1 and VPAC2 receptors mediate tactile hindpaw hypersensitivity and carotid artery dilatation induced by PACAP38 in a migraine relevant mouse model. J Headache Pain. 2024;25(1):126.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pellesi L, Al-Karagholi MA, De Icco R, et al. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Netw Open. 2021;4(8):e2118543.

Article  PubMed  PubMed Central  Google Scholar 

Ashina M, Phul R, Khodaie M, Löf E, Florea I. A monoclonal antibody to PACAP for migraine prevention. N Engl J Med. 2024;391(9):800–9.

Article  CAS  PubMed  Google Scholar 

Ashina M, Martelletti P. Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches? J Headache Pain. 2018;19(1):33.

Article  PubMed  PubMed Central  Google Scholar 

Edvinsson L, Tajti J, Szalárdy L, Vécsei L. PACAP and its role in primary headaches. J Headache Pain. 2018;19(1):21.

Article  PubMed  PubMed Central  Google Scholar 

May A, Schwedt TJ, Magis D, Pozo-Rosich P, Evers S, Wang SJ. Cluster headache. Nat Rev Dis Primers. 2018;4:18006.

Article  PubMed  Google Scholar 

Russell MB. Epidemiology and genetics of cluster headache. Lancet Neurol. 2004;3(5):279–83.

Article  PubMed  Google Scholar 

Petersen AS, Lund N, Goadsby PJ, et al. Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headache. Lancet Neurol. 2024;23(7):712–24.

Article  CAS  PubMed  Google Scholar 

Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L, Warfvinge K. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Neuroscience. 2012;202:158–68.

Article  CAS  PubMed  Google Scholar 

Akerman S, Goadsby PJ, Romero-Reyes M. PACAP-38 related modulation of the cranial parasympathetic projection: a novel mechanism and therapeutic target in severe primary headache. Br J Pharmacol. 2024;181(3):480–94.

Article  CAS  PubMed  Google Scholar 

Bacchelli E, Cainazzo MM, Cameli C, et al. A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants. J Headache Pain. 2016;17(1):114.

Article  PubMed  PubMed Central  Google Scholar 

Ran C, Fourier C, Michalska JM, et al. Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort. J Headache Pain. 2017;18(1):88.

Article  PubMed  PubMed Central  Google Scholar 

Tuka B, Szabó N, Tóth E, et al. Release of PACAP-38 in episodic cluster headache patients—an exploratory study. J Headache Pain. 2016;17(1):69.

Article  PubMed  PubMed Central  Google Scholar 

Vollesen ALH, Snoer A, Chaudhry B, et al. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache. Cephalalgia. 2020;40(13):1474–88.

Article  PubMed  Google Scholar 

Pellesi L, Chaudhry BA, Vollesen ALH, et al. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. Cephalalgia. 2022;42(8):687–95.

Article  PubMed  Google Scholar 

Deligianni C, Pellesi L, Chaudhry BA, et al. Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study. Front Neurol. 2023;14:1135246.

Article  PubMed  PubMed Central  Google Scholar 

Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

Chalmer MA, Kogelman LJA, Ullum H, et al. Population-based characterization of menstrual migraine and proposed diagnostic criteria. JAMA Netw Open. 2023;6(5):e2313235.

Article  PubMed  Google Scholar 

Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22(4):355–65.

Article